source
- #ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainCHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment with t…Endpoints · 1mo ago↗ source
- Opinion: The military’s medical corps has a serious recruitment problemCongress must incentivize more physicians (and their employers) to join the military medical corps, writes the former attending physician to Congress.STAT · 1mo ago↗ source
- Opinion: Medical schools diversified. So where are all the diverse doctors?Why are residency programs disciplining and dismissing trainees in a system funded to train them?STAT · 1mo ago